HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.

AbstractBACKGROUND:
To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking.
METHODS:
From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months.
RESULTS:
Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late > or = grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001).
DISCUSSION:
GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM.
AuthorsPirus Ghadjar, Jacqueline Vock, Daniel Vetterli, Peter Manser, Roland Bigler, Jan Tille, Axel Madlung, Frank Behrensmeier, Roberto Mini, Daniel M Aebersold
JournalRadiation oncology (London, England) (Radiat Oncol) Vol. 3 Pg. 35 (Oct 20 2008) ISSN: 1748-717X [Electronic] England
PMID18937833 (Publication Type: Journal Article)
Topics
  • Aged
  • Aged, 80 and over
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Prostatic Neoplasms (radiotherapy)
  • Radiation Injuries (etiology)
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated (adverse effects)
  • Recurrence
  • Risk
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: